[
  {
    "ts": null,
    "headline": "Novavax Pops on Pfizer Licensing Deal",
    "summary": "Matrix-M agreement adds cash and royalties",
    "url": "https://finnhub.io/api/news?id=20aeaf4432d54f712b677b7c1e01ac727652e6e429414185eb0ae143d9c132a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768931610,
      "headline": "Novavax Pops on Pfizer Licensing Deal",
      "id": 138188558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Matrix-M agreement adds cash and royalties",
      "url": "https://finnhub.io/api/news?id=20aeaf4432d54f712b677b7c1e01ac727652e6e429414185eb0ae143d9c132a4"
    }
  },
  {
    "ts": null,
    "headline": "Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up",
    "summary": "Pfizer exits ViiV Healthcare with a $1.89bn payout, while GSK retains its majority stake amid the shareholder shake-up.",
    "url": "https://finnhub.io/api/news?id=3e84dc06325d6f8ff2496b9de00676d9689284cd11a2bb7c086ec1c78e11ff3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768929246,
      "headline": "Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up",
      "id": 138188559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer exits ViiV Healthcare with a $1.89bn payout, while GSK retains its majority stake amid the shareholder shake-up.",
      "url": "https://finnhub.io/api/news?id=3e84dc06325d6f8ff2496b9de00676d9689284cd11a2bb7c086ec1c78e11ff3d"
    }
  },
  {
    "ts": null,
    "headline": "Novavax Licenses Rights to Key Vaccine Component to Pfizer",
    "summary": "Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer.  Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development and sales milestones are reached, plus royalties, Novavax said.  Pfizer, which makes an mRNA-based Covid-19 vaccine, is licensing Novavax’s adjuvant, called “Matrix-M,” which is a substance that can enhance the potency of a vaccine.",
    "url": "https://finnhub.io/api/news?id=d8c83e878eae7ce457680aa624cfdd4bb40ad81248a437d619818a311931e1d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768923666,
      "headline": "Novavax Licenses Rights to Key Vaccine Component to Pfizer",
      "id": 138188560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer.  Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development and sales milestones are reached, plus royalties, Novavax said.  Pfizer, which makes an mRNA-based Covid-19 vaccine, is licensing Novavax’s adjuvant, called “Matrix-M,” which is a substance that can enhance the potency of a vaccine.",
      "url": "https://finnhub.io/api/news?id=d8c83e878eae7ce457680aa624cfdd4bb40ad81248a437d619818a311931e1d0"
    }
  },
  {
    "ts": null,
    "headline": "Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science",
    "summary": "Abcam and the other 17 members of the partnership today launched the IHI project, LIGAND-AI, to advance AI-driven drug discovery through open science.",
    "url": "https://finnhub.io/api/news?id=803619f5597d69639328c6c43ac1ce3b5ddea95e4f1003c897244b39256a5a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768921200,
      "headline": "Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science",
      "id": 138187522,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Abcam and the other 17 members of the partnership today launched the IHI project, LIGAND-AI, to advance AI-driven drug discovery through open science.",
      "url": "https://finnhub.io/api/news?id=803619f5597d69639328c6c43ac1ce3b5ddea95e4f1003c897244b39256a5a64"
    }
  },
  {
    "ts": null,
    "headline": "CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?",
    "summary": "CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.",
    "url": "https://finnhub.io/api/news?id=b9765f0e10f88e98610b23da994c0a9608796cd79cbf149ebc0a80dabef5c57e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768919880,
      "headline": "CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?",
      "id": 138187523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.",
      "url": "https://finnhub.io/api/news?id=b9765f0e10f88e98610b23da994c0a9608796cd79cbf149ebc0a80dabef5c57e"
    }
  },
  {
    "ts": null,
    "headline": "Which Pharma Stock Stands Taller Right Now: LLY or PFE?",
    "summary": "Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case against peers.",
    "url": "https://finnhub.io/api/news?id=ee6e7705b683cddfed586b09c3c6466ee59108c6304fbf023f2979bd386e7293",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768914480,
      "headline": "Which Pharma Stock Stands Taller Right Now: LLY or PFE?",
      "id": 138187432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case against peers.",
      "url": "https://finnhub.io/api/news?id=ee6e7705b683cddfed586b09c3c6466ee59108c6304fbf023f2979bd386e7293"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer CEO Albert Bourla: U.S. drug prices are coming down",
    "summary": "Albert Bourla, CEO of Pfizer, joins 'Money Movers' to discuss drug pricing, the impact on artificial intelligence on healthcare, and more.",
    "url": "https://finnhub.io/api/news?id=520ac3e81ae39c00c118a98efc90e19bc4e86487f881eea73099cda414d19036",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768911637,
      "headline": "Pfizer CEO Albert Bourla: U.S. drug prices are coming down",
      "id": 138188165,
      "image": "https://image.cnbcfm.com/api/v1/image/108254405-17689284591768928456-43594105241-1080pnbcnews.jpg?v=1768928458&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Albert Bourla, CEO of Pfizer, joins 'Money Movers' to discuss drug pricing, the impact on artificial intelligence on healthcare, and more.",
      "url": "https://finnhub.io/api/news?id=520ac3e81ae39c00c118a98efc90e19bc4e86487f881eea73099cda414d19036"
    }
  },
  {
    "ts": null,
    "headline": "Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry",
    "summary": "Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.",
    "url": "https://finnhub.io/api/news?id=a2b8109ab9f0a21a179e533bf84322fb5f4112fed535176f1f27dd22755ee9dc",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768911513,
      "headline": "Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry",
      "id": 138188129,
      "image": "https://image.cnbcfm.com/api/v1/image/108244385-1766176930135-gettyimages-2252075211-TRUMP_DRUG_PRICING.jpeg?v=1766176955&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs. ",
      "url": "https://finnhub.io/api/news?id=a2b8109ab9f0a21a179e533bf84322fb5f4112fed535176f1f27dd22755ee9dc"
    }
  },
  {
    "ts": null,
    "headline": "Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged",
    "summary": "Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.",
    "url": "https://finnhub.io/api/news?id=29eb1b73de3a68aad76b4ce27ece84f3cb32f6b1356d04dcd510e0c438ca2f2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768895656,
      "headline": "Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged",
      "id": 138186415,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.",
      "url": "https://finnhub.io/api/news?id=29eb1b73de3a68aad76b4ce27ece84f3cb32f6b1356d04dcd510e0c438ca2f2b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Valuation Check As Investors Reassess Recent Shareholder Returns",
    "summary": "Why Pfizer (PFE) Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the stock showing positive total returns over the past year despite weaker recent annual revenue and net income growth. See our latest analysis for Pfizer. Recent trading has been relatively steady, with a 90 day share price return of 3.22% and a 1 year total shareholder return of 4.59%, contrasting with a weaker 3 year total shareholder return of 32.17%...",
    "url": "https://finnhub.io/api/news?id=97df00c11c0f727e7b4cce6333ddb7b20cd1f33bfe8fea09f9dbb9bbb5afc499",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768867970,
      "headline": "Pfizer (PFE) Valuation Check As Investors Reassess Recent Shareholder Returns",
      "id": 138181954,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Why Pfizer (PFE) Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the stock showing positive total returns over the past year despite weaker recent annual revenue and net income growth. See our latest analysis for Pfizer. Recent trading has been relatively steady, with a 90 day share price return of 3.22% and a 1 year total shareholder return of 4.59%, contrasting with a weaker 3 year total shareholder return of 32.17%...",
      "url": "https://finnhub.io/api/news?id=97df00c11c0f727e7b4cce6333ddb7b20cd1f33bfe8fea09f9dbb9bbb5afc499"
    }
  }
]